Financial Performance - The company reported a significant increase in revenue for the first half of 2024, achieving a total of 500 million yuan, representing a growth of 25% year-over-year[1]. - The company's operating revenue for the first half of 2024 was approximately ¥880.69 million, representing a year-on-year increase of 1.08% compared to ¥871.31 million in the same period last year[14]. - The net profit attributable to shareholders of the listed company decreased by 33.99% to approximately ¥220.21 million, down from ¥333.61 million in the same period last year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥210.69 million, a decrease of 31.86% compared to ¥309.21 million in the same period last year[14]. - The company's net cash flow from operating activities was approximately ¥155.21 million, down 45.53% from ¥284.96 million in the same period last year[14]. - The total assets at the end of the reporting period were approximately ¥9.93 billion, down 1.49% from ¥10.08 billion at the end of the previous year[14]. - The company achieved operating revenue of 880.69 million yuan, a year-on-year increase of 1.08%[15]. - Net profit attributable to shareholders decreased by 33.99% to 220.21 million yuan, while net profit after deducting non-recurring gains and losses fell by 31.86% to 210.69 million yuan[15]. - Basic earnings per share decreased by 33.75% to 0.53 yuan, and diluted earnings per share also decreased by 33.75% to 0.53 yuan[15]. - The weighted average return on equity decreased by 1.13 percentage points to 2.29%[15]. Research and Development - The company has invested 50 million yuan in new technology for vaccine production, aiming to improve efficiency by 40%[1]. - The board has approved a plan to reinvest 30% of profits into R&D for the next fiscal year to drive innovation[1]. - R&D expenditure accounted for 27.87% of operating revenue, an increase of 4.22 percentage points compared to the same period last year[15]. - The total R&D investment for the reporting period reached approximately CNY 245.45 million, an increase of 19.11% compared to the previous year[37]. - The company is actively developing a pipeline of vaccines, including a quadrivalent influenza vaccine and a 15-valent HPV vaccine, leveraging its advanced technology platforms[19]. - The company has established four major R&D technology platforms: bacterial vaccines, viral vaccines, multi-valent vaccines, and recombinant protein vaccines[42]. - The company is focusing on developing a series of innovative combination vaccines, particularly advantageous for the adolescent population[33]. - The company has achieved significant progress in its vaccine development pipeline, with multiple products expected to reach the market soon[38]. - The company has filed 18 new intellectual property applications during the reporting period, including 6 invention patents, bringing the total number of patents to 168[35]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share in the region by the end of 2025[1]. - New product launches are expected to contribute an additional 300 million in revenue by Q4 2024[102]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million allocated for potential deals[105]. - The company is actively exploring mRNA vaccine technology platform development alongside its existing bacterial, viral, multivalent, and recombinant protein vaccine platforms[29]. - The company is focusing on the biotechnology sector, actively seeking investment opportunities in innovative vaccine products and related biopharmaceutical technologies[51]. Risks and Challenges - The management has identified potential risks related to regulatory changes, which could impact future product approvals and market entry[1]. - The company faces risks from the loss of core technical personnel, which could delay ongoing projects and hinder future development[58]. - The current product structure is relatively single, primarily relying on rabies and Japanese encephalitis vaccines, which poses risks if market conditions fluctuate[59]. - The company faces exchange rate risks due to foreign currency transactions, particularly in vaccine exports and raw material purchases[67]. - The demand for human rabies vaccines in China may decline as the rabies prevention system improves, but the company is prepared to mitigate this risk through increased R&D investment[68]. Environmental and Social Responsibility - The company has implemented pollution control measures including high-temperature steam sterilizers and wastewater treatment facilities, ensuring stable operation[86]. - The company has established an environmental management system certified under GB/T 24001-2016/ISO 14001:2015, ensuring compliance with environmental laws and regulations[93]. - The company actively implements carbon reduction measures, including the use of clean energy and promoting resource recycling to minimize greenhouse gas emissions[94]. - The company has established emergency response plans for environmental incidents, with a validity of three years[88]. - The company reported an average COD discharge concentration of 23.04 mg/L, significantly below the regulatory standard of 300 mg/L, with a total discharge of 3.37 tons during the reporting period[91]. Shareholder and Corporate Governance - The company has committed to maintaining shareholder value, with a promise of no share buybacks for the next 36 months[101]. - The board of directors has approved a new dividend policy, increasing the payout ratio to 30% of net income starting from Q3 2024[102]. - The company will ensure that cash dividends do not exceed the cumulative distributable profit range[111]. - The profit distribution plan must be approved by more than two-thirds of the voting rights at the shareholders' meeting[113]. - The company guarantees strict adherence to commitments regarding related party transactions and will compensate for any losses incurred due to violations[117]. Operational Highlights - The company has established partnerships with three major healthcare providers to enhance distribution channels for its products[1]. - The company maintains a leading position in the human rabies vaccine market, with a market share that has been dominant for over a decade[19]. - The company has developed a core technology for large-scale vaccine production, which has filled a domestic gap and won a provincial award for its contribution to rabies prevention[28]. - The company has implemented a flexible production plan to ensure stable vaccine supply, considering market demand and inventory safety[48]. - The company achieved operating revenue of 880.69 million yuan, a year-on-year increase of 1.08%, while net profit attributable to shareholders decreased by 33.99% to 220.21 million yuan[46].

证券代码：688739 证券简称：成大生物 公告编号：2024-029 次回购股份情况，具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披 露的《关于第二次以集中竞价交易方式回购公司股份的首次回购公告》（公告编号： 2024-006）。 关于第二次股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/3/12 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 2,500 万元~5,000 万元 | | 回购价格上限 | 元/股 42.00 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 股 1,832,267 | | 实际回购股数占总股本比例 | 0.44% | | 实际回购金额 | 49,993,325.75 元 | | 实际回购价格区间 | 元/股~2 ...

证券代码：688739 证券简称：成大生物 公告编号：2024-028 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7 号——回购股份》的相关规定，现将公司回购股份进展情况公告如下： 辽宁成大生物股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/3/12 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过后 12 个月内 | | 预计回购金额 | 万元 2,500 万元~5,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,617,267 股 | | 累计已回购股数占总股本比例 | 0.388% | | 累计已回购金额 | 44,759,583.56 元 | | 实际回购价格区间 | 27.23 元/股~28.15 元/股 | 一、 回购股份的基本情况 ...

证券代码：688739 证券简称：成大生物 公告编号：2024-027 辽宁成大生物股份有限公司 关于核心技术人员离职暨新增认定核心技术人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 司常务副总经理，负责公司细菌性疫苗和创新疫苗的研发。2020年4月至2024年 6月，任公司核心技术人员。 （二）专利情况 孙述学先生在公司担任核心技术人员期间参与了公司的技术研发相关工作， 期间参与申请的专利均非单一发明人的专利且均为职务发明创造。前述专利所有 权均属于公司，不存在涉及专利纠纷或潜在纠纷，其不再担任核心技术人员不会 对公司专利权的完整性产生影响。 重要内容提示： 辽宁成大生物股份有限公司（以下简称"成大生物"或"公司"）核心技 术人员孙述学先生因个人原因申请辞去所任职务及核心技术人员身份，已办理完 成相关离职手续及工作交接，离职后不再担任公司任何职务。 孙述学先生负责的工作已完成交接。目前公司的技术研发工作均正常进行， 孙述学先生离职不会对公司整体技术研发和持续经营能力产生重大不利影响，也 不会对公司核心竞争力产 ...

中信证券股份有限公司 孙述学先生在公司担任核心技术人员期间参与了公司的技术研发相关工作， 期间参与申请的专利均非单一发明人的专利且均为职务发明创造。前述专利所有 权均属于公司，不存在涉及专利纠纷或潜在纠纷，其不再担任核心技术人员不会 关于辽宁成大生物股份有限公司 核心技术人员离职暨新增认定核心技术人员的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为辽宁成大 生物股份有限公司（以下简称"成大生物"或"公司"）首次公开发行股票的保荐机 构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关规 定，对成大生物核心技术人员离职暨新增认定核心技术人员事项发表核查意见如 下： 一、公司核心技术人员离职的具体情况 公司原核心技术人员孙述学先生因个人原因申请辞去所任职务及核心技术 人员身份，已办理完成相关离职手续及工作交接，离职后不再担任公司任何职务。 （一）孙述学先生具体情况 孙述学，男，1967年10月出生，中国国籍，无境外永久居留权，硕士，研究 员，研究生导师。本科毕业于中国农业大学，研究生毕业于兰州生 ...

证券代码：688739 证券简称：成大生物 公告编号：2024-026 辽宁成大生物股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/6/19 | 2024/6/20 | 2024/6/20 | 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东， 公司回购专用证券账户除外。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章及其 他规范性文件以及《公司章程》的有关规定，公司回购的股份不享有股东大会表决 权、利润分配、公积金转增股本、认购新股和配股等权利。 是否涉及差异化分红送转：是 每股分配比例 每股现金红利 0.80 元（含税） 相关日期 3. 差异化分红送转方案： （ ...

中信证券股份有限公司 关于辽宁成大生物股份有限公司 差异化权益分派特殊除权除息事项的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为辽宁成 大生物股份有限公司（以下简称"成大生物"或"公司"）首次公开发行股票的 保荐机构，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）及《上海证券交易所上市公司自律监管 指引第 7 号——回购股份》等相关规定，对成大生物差异化权益分派特殊除权除 息事项发表核查意见如下： 一、本次实施差异化分红的原因 2023年9月15日，公司召开第五届董事会第五次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》，同意公司使用不低于人民币5,000 万元（含）且不超过人民币10,000万元（含）的超募资金以集中竞价交易方式回 购公司人民币普通股股票，用于实施员工持股计划或股权激励。回购股份的价格 为不超过人民币45.00元/股，回购股份期限为自公司董事会审议通过本次回购股 份方案之日起不超过12个月。 截至 2023 年 12 月 20 日，公司已完成股份回购，已实际回购公司股份 2,982, ...

二、实施回购股份的进展情况 证券代码：688739 证券简称：成大生物 公告编号：2024-025 辽宁成大生物股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至2024年5月31日，辽宁成大生物股份有限公司（以下简称"公司"）通 过上海证券交易所交易系统以集中竞价交易方式已累计回购公司股份1,617,267 股，占公司总股本的比例为0.388%，回购成交的最高价为28.15元/股，最低价为 27.23元/股，已支付的资金总额为人民币44,759,583.56元。 一、回购股份的基本情况 公司于2024年3月8日召开第五届董事会第八次会议，审议通过了《关于第二 次以集中竞价交易方式回购股份方案的议案》。公司拟使用不低于人民币2,500万 元（含）且不超过人民币5,000万元（含）的超募资金以集中竞价交易方式回购公 司人民币普通股股票，用于实施员工持股计划或股权激励，回购股份的价格为不 超过人民币42.00元/股（含），回购股份期限为自公司董事会审 ...

辽宁成大生物股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 5 月 14 日 （二） 股东大会召开的地点：辽宁省沈阳市浑南区新放街 1 号 辽宁成大生物股 份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 27 | | --- | --- | | 普通股股东人数 | 27 | | 2、出席会议的股东所持有的表决权数量 | 244,051,777 | | 普通股股东所持有表决权数量 | 244,051,777 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 58.6028 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 58.6028 | 证券代码：688739 证券简称：成大生物 公告编号：2024- ...